Interaction between erythromycin and the benzodiazepines diazepam and flunitrazepam

被引:18
作者
Luurila, H
Olkkola, KT
Neuvonen, PJ
机构
[1] Department of Clinical Pharmacology, University of Helsinki, FIN-00250 Helsinki
来源
PHARMACOLOGY & TOXICOLOGY | 1996年 / 78卷 / 02期
关键词
D O I
10.1111/j.1600-0773.1996.tb00191.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The effect of erythromycin on the pharmacokinetics and pharmacodynamics of diazepam and flunitrazepam was investigated in two randomized, double-blind, cross-over studies. Healthy volunteers ingested erythromycin for one week 500 mg t.i.d. On the 4th day they ingested a single 5 mg dose of diazepam (6 subjects, Study 1) or 1 mg dose of flunitrazepam (5 subjects, Study 2), respectively. Plasma drug concentrations and psychomotor effects were measured during 42 hr after the ingestion of diazepam or flunitrazepam. In Study 1 erythromycin increased the area under the diazepam plasma concentration-time curve [AUG (0-42 hr)] by 15% (P<0.05) and the concentration of diazepam in plasma at 42 hr by 63% (P<0.05). The median peak concentration (C-max and the half-life (t(1/2)) of diazepam were increased but they did not change significantly (P=0.17 and 0.12, respectively). Plasma N-desmethyldiazepam concentrations were slightly reduced during erythromycin treatment up to 8 hr (P<0.05). In Study 2 the AUC (0-42 hr) of flunitrazepam was increased by 25% (P<0.05) during the erythromycin treatment. The t(1/2) of flunitrazepam increased significantly (P<0.05), but the C-max remained unchanged. The psychomotor effects of diazepam or flunitrazepam were not changed significantly by erythromycin. These pharmacokinetic interactions can be explained by the reduced metabolic elimination of diazepam and flunitrazepam. The interactions of erythromycin with diazepam and flunitrazepam seem to be slight and of limited clinical significance only.
引用
收藏
页码:117 / 122
页数:6
相关论文
共 29 条
[1]   OMEPRAZOLE DRUG-INTERACTION STUDIES [J].
ANDERSSON, T .
CLINICAL PHARMACOKINETICS, 1991, 21 (03) :195-212
[2]   DIAZEPAM METABOLISM BY HUMAN LIVER-MICROSOMES IS MEDIATED BY BOTH S-MEPHENYTOIN HYDROXYLASE AND CYP3A ISOFORMS [J].
ANDERSSON, T ;
MINERS, JO ;
VERONESE, ME ;
BIRKETT, DJ .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1994, 38 (02) :131-137
[3]   THE EFFECT OF ERYTHROMYCIN ON THE PHARMACOKINETICS AND PHARMACODYNAMICS OF ZOPICLONE [J].
ARANKO, K ;
LUURILA, H ;
BACKMAN, JT ;
NEUVONEN, PJ ;
OLKKOLA, KT .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1994, 38 (04) :363-367
[4]   IMPORTANCE OF GENETIC-FACTORS IN THE REGULATION OF DIAZEPAM METABOLISM - RELATIONSHIP TO S-MEPHENYTOIN, BUT NOT DEBRISOQUIN, HYDROXYLATION PHENOTYPE [J].
BERTILSSON, L ;
HENTHORN, TK ;
SANZ, E ;
TYBRING, G ;
SAWE, J ;
VILLEN, T .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1989, 45 (04) :348-355
[5]   USE OF ANALOG SCALES IN RATING SUBJECTIVE FEELINGS [J].
BOND, A ;
LADER, M .
BRITISH JOURNAL OF MEDICAL PSYCHOLOGY, 1974, 47 (SEP) :211-218
[6]   ASSESSMENT OF LIVER METABOLIC FUNCTION - CLINICAL IMPLICATIONS [J].
BROCKMOLLER, J ;
ROOTS, I .
CLINICAL PHARMACOKINETICS, 1994, 27 (03) :216-248
[7]   FLUVOXAMINE IS A POTENT INHIBITOR OF CYTOCHROME-P4501A2 [J].
BROSEN, K ;
SKJELBO, E ;
RASMUSSEN, BB ;
POULSEN, HE ;
LOFT, S .
BIOCHEMICAL PHARMACOLOGY, 1993, 45 (06) :1211-1214
[8]   SIMULTANEOUS DETERMINATION OF MIDAZOLAM AND ITS 3 HYDROXY METABOLITES IN HUMAN-PLASMA BY ELECTRON-CAPTURE GAS-CHROMATOGRAPHY WITHOUT DERIVATIZATION [J].
DEKROON, IFI ;
LANGENDIJK, PNJ ;
DEGOEDE, PNFC .
JOURNAL OF CHROMATOGRAPHY-BIOMEDICAL APPLICATIONS, 1989, 491 (01) :107-116
[9]  
Gibaldi M. P., 1982, PHARMACOKINETICS
[10]   PHARMACOKINETIC DRUG-INTERACTIONS WITH ANTIMICROBIAL AGENTS [J].
GILLUM, JG ;
ISRAEL, DS ;
POLK, RE .
CLINICAL PHARMACOKINETICS, 1993, 25 (06) :450-482